Low-Dose Bevacizumab Maintains Efficacy With Reduced Adverse Events in Liver Cancer. - Lin PT; Teng W; Hsieh YC; Wu TH; Chen WT; Lin CC; Lin SM; Lin CY (Liver international : official journal of the International Association for the Study of the Liver, 2026)